The expansion of manufacturing capacity is an ongoing process. Much depends on research and development results. One promising approach is the incorporation of adjuvants (agents to enhance the immune response), thereby allowing smaller quantities of the vaccine itself to be used, expanding the numbers of available doses. The Department is in close touch with both industry development plans and the international initiatives to increase vaccine manufacturing capacity.